1. A crystalline pressor substance (Angiotonin) resulting from the reaction between renin and renin-activator

2. Refer to Aldosterone/Renin Activity Ratio ( 0070073 ) or Aldosterone and Renin, Direct with Ratio ( 2002582 ).

3. In liver cirrhosis no significant inverse relationship between renin activity and renin substrate lovel was observed.

4. A kinetic analysis of the renin-Angiotonin pressor system and the standardization of the enzymes renin and angiotonase

5. The renin-Angiotensin-aldosterone system (RAAS), or renin-Angiotensin-system (RAS) is a regulator of blood pressure and cardiovascular function

6. The renin-angiotensin-Aldosterone system (RAAS), or renin-angiotensin-system (RAS) is a regulator of blood pressure and cardiovascular function

7. Patients with strongly activated renin-angiotensin-aldosterone system

8. Dual blockade of the renin-angiotensin-aldosterone system

9. Renin is an enzyme that controls Aldosterone production

10. Plasma aldosterone and renin activity was low throughout anesthesia.

11. Renin is present in plasma of patients with primary aldosteronism.

12. There was no correlation between blood pressure and plasma renin activity.

13. In analbuminaemia renin secretion is increased when albumin is completely lacking.

14. The combined Aldosterone/renin tests are preferred when screening for hyperaldosteronism

15. Primary Aldosteronism is measured by a patient’s aldosterone-renin ratio (ARR)

16. The kidney hormone renin normally stimulates the adrenal glands to release Aldosterone.

17. It is part of the renin–angiotensin system, which regulates blood pressure.

18. Doxazosin may influence the plasma renin activity and urinary excretion of vanillylmandelic acid

19. Myocardial fibrosis is associated with activated circulating or local renin-angiotensin-aldosterone systems.

20. The final product, a pressor substance formed through the interaction of renin and its activator, was named Angiotonin 38–41 and was, probably, the actual effector of the renin pressor action

21. Angiotensin I is a ten amino acid peptide formed by renin cleavage of Angiotensinogen

22. Angiotensin consists of a group of hormones that are part of the renin-Angiotensin system.

23. The renin-angiotensin-aldosterone system involving the kidney and adrenal gland is another responding system.

24. Reduced Na+ evokes renin release, which stimulates Aldosterone secretion; Aldosterone may be measured when evaluating hypertension.

25. Furthermore, plasma renin activity (PRA), plasma cortisol, plasma sodium concentration and plasma potassium concentration were measured.

26. 14 Renin and atrial natriuretic peptide restriction fragment length polymorphisms: association with ethnicity and blood pressure.

27. The renin–angiotensin system is targeted at different points by many of the commonly used Antihypertensive drugs.

28. As with others drugs acting on the renin-angiotensin-aldosterone system, telmisartan may provoke hyperkalaemia (see section

29. In both species, increased plasma renin activity and hypertrophy/hyperplasia of the renal juxtaglomerular cells were observed

30. A good stimulation of the plasma aldosterone in spite of the lack of stimulation of the plasma renin activity, demonstrates that in our experiments the renin-angiotensin system cannot be responsible for the increase in aldosterone secretion under salt depletion.

31. The renin-Angiotensin-aldosterone system (RAAS) plays an important role in regulating blood volume and systemic vascular resistance, which together influence cardiac output and arterial pressure.As the name implies, there are three important components to this system: 1) renin, 2) Angiotensin…

32. The data suggest that propranolol at the dose administered suppresses renin and aldosterone secretion in unstimulated dogs.

33. Angiotensinogen is a precursor protein produced in the liver and cleaved by renin to form Angiotensin I

34. Renin–angiotensin system (RAS): This system is generally known for its long-term adjustment of arterial pressure.

35. Investigations in man have shown that indomethacin causes a reduction in plasma renin activity (PRA) and sodium retention.

36. The plasma aldosterone-renin ratio (ARR) is a valid screening assay for primary Aldosteronism, but antihypertensives are usually

37. It is concluded that the increased plasma (serum) renin activity in diabetes insipidus originates in the juxtaglomerular apparatus.

38. : a glycoprotein formed chiefly in the liver that is cleaved by renin to produce Angiotensin I The enzyme renin affects blood pressure and electrolyte homeostasis by catalyzing the formation of Angiotensin I from circulating Angiotensinogen … — Nicola Glorioso et al., Science, 26 Sept

39. Plasma concentrations of angiotensin I, angiotensin II and of saralasin as well as plasma renin activity were measured.

40. These juxtaglomerular cells play a major role in the renin–angiotensin system, which helps regulate blood volume and pressure.

41. It sensitizes the intestine to further doses of Angiotonin and alters the intestine such that renin-activator contracts it

42. The diagnosis of primary Aldosteronism starts with a blood test called aldosterone renin ratio. The test is not standardized

43. Focus topic: Antihypertensives A selective renin inhibitor, aliskiren [a-LIS-ke-rin], is available for the treatment of hypertension

44. The pivotal role of melatonin in Ameliorating chronic kidney disease by suppression of the renin-angiotensin system in the kidney.

45. These tests measure the levels of Aldosterone and renin in the blood and/or the level of Aldosterone in urine

46. The renin-Angiotensin system (RAS) plays a key role in maintaining blood pressure homeostasis, as well as fluid and salt balance

47. Plasma samples were collected to measure the renin-angiotensin system (RAS) activities and reactive oxygen species levels by radioimmunoassay, Chromatometry and ELISA

48. Aldosterone, LC/MS - Approximately 1-2% of individuals with primary hypertension have primary hyperaldosteronism characterized by hypokalemia (low potassium) and low direct renin

49. Presumably through blockade of the renin-angiotensin-aldosterone system, co-administration of telmisartan tends to reverse the potassium loss associated with these diuretics

50. This animation focuses on the renin Angiotensin aldosterone system (RAAS), a classic endocrine system that helps to regulate long-term blood pressure and ext

51. Angio-tensinogen is then converted to Angiotensin I by renin, and then to active Angiotensin II by Angiotensin-converting enzyme (ACE) in the lungs.

52. Angiotensin receptor blockers (Arbs) and angiotensin-converting enzyme (ACE) inhibitors are highly utilized classes of medications that affect the renin-angiotensin-aldosterone system (RAAS)

53. Heart failure As a consequence of the inhibition of the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals

54. Atrial natriuretic factor (ANF) a hormone produced in the cardiac atrium; it inhibits renin secretion and thus the production of angiotensin, and stimulates aldosterone release

55. atrial natriuretic factor (Anf) a hormone produced in the cardiac atrium; it inhibits renin secretion and thus the production of angiotensin , and stimulates aldosterone release

56. Plasma concentrations of antidiuretic hormone (ADH), adrenocorticotropic hormone (ACTH), epinephrine, norepinephrine, aldosterone, plasma renin activity, Cortisol, and insulin were measured simultaneously during and following endotoxic hypotension.

57. Any short term derangements are dealt via the Baroreceptor response, whereas long term control of the BP is controlled via the RAAS (Renin Angiotensin Aldosterone System).

58. Angiotensin I is produced by the action of renin (an enzyme produced by the kidneys) on a protein called Angiotensinogen, which is formed by the liver.

59. The renin-aldosterone link is mediated by angiotensin # and therefore coadministration of an angiotensin # receptor antagonist tends to reverse the potassium loss associated with thiazide diuretics

60. Ionic and Osmotic Effects Changes in external juxtaglomerular osmolarity, such as those observed in Amphiuma, may mediate the renin secretory response to a change of luminal NaCl.

61. In 4 out of 8 patients with secondary aldosteronism or adrenal insufficiency and 4 out of 16 hypertensive patients plasma renin activity is increased by angiotensin infusion.

62. The high-pressure or arterial Baroreceptors and low-pressure or atrial receptors are believed to participate in the reflex control of arginine vasopressin (AVP) and renin secretion

63. In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with NATRECOR may be associated with azotemia.

64. Angiotensin I (Ang I) (C62H89N17O14), with the sequence H-Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu-OH, is formed by the action of renin on Angiotensinogen

65. What is Angiotensin? The liver creates and releases a protein called Angiotensinogen. This is then broken up by renin, an enzyme produced in the kidney, to form Angiotensin I

66. Primary aldosteronism (PA), also known as primary hyperaldosteronism or Conn's syndrome, refers to the excess production of the hormone Aldosterone from the adrenal glands, resulting in low renin levels

67. The diuretic action of hydrochlorothiazide reduces plasma volume, increases plasma renin activity, increases aldosterone secretion, with consequent increases in urinary potassium and bicarbonate loss, and decreases in serum potassium

68. Norepinephrine in pressor doses causes in part a decrease of plasma renin activity in patients with secondary aldosteronism or adrenal insufficiency and an increase in the normotensive and hypertensive groups.

69. When renin levels are elevated, the concentrations of angiotensin II and aldosterone increase, leading to increased sodium chloride reabsorption, expansion of the extracellular fluid compartment, and an increase in blood pressure.

70. Aldosterone, acting as a mineralocorticoid, is the final endocrine signal in the renin-angiotensin-Aldosterone system that targets epithelia in the kidney and colon to regulate Na + (re)absorption and K + secretion

71. The 825T allele is significantly associated with an increased risk for hypertension in Caucasians, most likely “low renin hypertension” and it accumulates significantly in individuals with a strong family history of hypertension.

72. Our data suggest that the administration of methylprednisolone or dexamethasone is beneficial in improving endotoxic shock by decreasing the plasma levels of vasoactive hormones such as ADH and the renin-angiotensin-aldosterone system.

73. It sensitizes the intestine to further doses of Angiotonin and alters the intestine such that renin-activator contracts it. Angiotonin also constricts the vessels of a rabbit's ear perfused with blood or Ringer's solution.

74. Angiotensin The vasoconstrictor polypeptide hormone, Angiotensin II, which is released by the action of the enzyme renin. Its precursor, Angiotensin I, is inactive until acted on by the Angiotensin-converting enzyme, mainly in the lungs

75. In 7 patients with hypertension, aldosteronism, and low plasma renin (6 patients with a solitary adrenal adenoma, 1 patient with bilateral adrenal hyperplasia) circulatory reflexes (Valsalva's maneuver, head-up tilt and cold pressure test) were examined.

76. Subtypes of primary Aldosteronism — Renin-independent, incompletely suppressible (primary) hypersecretion of aldosterone is an increasingly recognized, but still underdiagnosed, cause of hypertension ; it is estimated to be responsible up to 10 percent of hypertension in humans .

77. We conclude that increased plasma aldosterone may result in up-regulation of vascular angiotensin II receptors independently of changes in plasma renin activity, and may in certain physiological states effectively antagonize the down-regulating action of angiotensin II.

78. Hyperkalaemia: as with other medicinal products that affect the renin-angiotensin-aldosterone system, hyperkalaemia may occur during the treatment with Aprovel, especially in the presence of renal impairment, overt proteinuria due to diabetic renal disease, and/or heart failure

79. Hyperkalaemia: as with other medicinal products that affect the renin-angiotensin-aldosterone system, hyperkalaemia may occur during the treatment with Karvea, especially in the presence of renal impairment, overt proteinuria due to diabetic renal disease, and/or heart failure

80. Angiotensin II is the major bioactive product of the renin-Angiotensin system, binding to receptors on intraglomerular mesangial cells, causing these cells to contract along with the blood vessels surrounding them and causing the release of aldosterone from the adrenal cortex.